Pharmacokinetics and Safety of Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infectio
- Conditions
- ChickenpoxHerpes ZosterTherapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- EUCTR2015-004442-25-Outside-EU/EEA
- Lead Sponsor
- ovartis Pharmaceuticals
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- A
- Sex
- All
- Target Recruitment
- 76
Inclusion Criteria
•Male or female children 1-12 years of age
•Clinical or laboratory evidence of varicella zoster infection
•Patients suspected of having varicella zoster infection
Are the trial subjects under 18? yes
Number of subjects for this age range: 76
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
•Patients unable to swallow
•Concomitant use of probenecid
•Positive pregnancy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method